Literature DB >> 3782262

Chemotherapy in intracerebrally transplanted tumors induced with transplacental administration of ethylnitrosourea in rats.

H D Mennel, D Hellwig, H Simon.   

Abstract

Four tumors of the spinal cord were induced with ethylnitrosourea in rats by transplacental administration and transplanted into the brains of animals of the same strain. One of these intracerebrally grafted tumor lines (G-XIII) was followed up over the first 10 passages and treated with CCNU and other alkylating drugs. The results were compared with findings in an earlier established line (G-XII) in passage 12 and 59, which in the first instance was sensitive to CCNU. The CCNU application prolonged survival in treated animals in various treatment schedules in the first 10 intracerebrally grafted generations of the tumor up to 59%. Induction times of tumors became increasingly shorter. The susceptibility of early passages was similar in both lines. Its loss in late passages went together with diffuse growth of the tumor and reticulin fiber production. In addition, glial fibrillary acid protein expression and formation of intermediate filaments in perivascular tumor cells was lost.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3782262     DOI: 10.1007/bf00395918

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  11 in total

1.  The endothelial hyperplasia of the cerebral blood vessels with brain tumors, and its sarcomatous transformation.

Authors:  I FEIGIN; L B ALLEN; L LIPKIN; S W GROSS
Journal:  Cancer       Date:  1958 Mar-Apr       Impact factor: 6.860

2.  Development of an animal brain tumor model and its response to therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  M Barker; T Hoshino; O Gurcay; C B Wilson; S L Nielsen; R Downie; J Eliason
Journal:  Cancer Res       Date:  1973-05       Impact factor: 12.701

3.  Quantitative aspects of transplantation of experimentally induced tumors of the nervous system.

Authors:  H D Mennel; P Groneck
Journal:  Acta Neuropathol       Date:  1977-10-10       Impact factor: 17.088

4.  [The effects of combined chemotherapy (adriamycin/VM/26/CCNU) in brian tumours in adults and animal experiments (author's transl)].

Authors:  H W Ilsen; I N Petrovici; H D Mennel; K J Zülch; J Szymas
Journal:  Fortschr Neurol Psychiatr       Date:  1982-03       Impact factor: 0.752

5.  Experimental ependymomas: in vivo and in vitro morphology.

Authors:  H D Mennel; J Bücheler
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1974

6.  Short-term tissue culture observations of experimental primary and transplanted nervous system tumors.

Authors:  H D Mennel
Journal:  J Neuropathol Exp Neurol       Date:  1980-11       Impact factor: 3.685

7.  Morphology of transplacentally induced nervous system tumors in rats: some aspects of this model in neurooncology.

Authors:  H D Mennel
Journal:  Int J Biol Res Pregnancy       Date:  1982

8.  Brain tumor chemotherapy using a rat glioma model.

Authors:  M Tamura; H D Mennel; K J Zülch
Journal:  J Cancer Res Clin Oncol       Date:  1979-05-14       Impact factor: 4.553

9.  Significance of experimental models in neurooncology.

Authors:  H D Mennel
Journal:  Neurosurg Rev       Date:  1980       Impact factor: 3.042

10.  Morphology of early stages of ENU-induced brain tumors in rats.

Authors:  H D Mennel; H Simon
Journal:  Exp Pathol       Date:  1985
View more
  2 in total

1.  The intraneoplastic chemotherapy in a rat brain tumour model utilizing methotrexate-polymethylmethacrylate-pellets.

Authors:  B Rama; T Mandel; J Jansen; E Dingeldein; H D Mennel
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

Review 2.  What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma.

Authors:  S Amarasingh; M R Macleod; I R Whittle
Journal:  J Neurooncol       Date:  2008-09-24       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.